Hi everybody,
I am mom to a 15 year old daughter with CF. She has not had an easy path with her CF so far although I'm certain some have had a lot worse. But at 15 she has a port (usually on IV antibiotics 2-6 weeks/year) and has CFRD. She also had a gtube from age 5-14. Even with all those challenges however, she has remained a positive, optimistic person and has always been super compliant with her CF meds and treatments.
But it has been a tough year. She started high school in September.Right before that her CF doc had put her on prednisone then medrol. Shestarted feeling really depressed, moody, not sleeping, etc. Every side effect in the book. She even beganhaving some weird dream like"terrors" at night. Like someone or something was after her. Not unusual when on steroids from what I understand.
But recently, she has had these night "terrors" again. Or more accurately, she has REALIZED she's been having them for a long time. Frighting stuff. Spiders or scary people coming after her. No wonder she was always exhausted in the mornings and found it impossible to get to school. Then I came across the information below about Singulair. Has anyone else experienced anything like this? We have taken her off the Singulair and she seemed at first to be better. But lately she is still bothered by these terror type of events at night. I'm thinking that she was on prednisone and then singulair for so long and suffering with these terrors for so long that they are not just going to go away overnight when we stop the meds. Does anyone else have any experience with this sort of event?
<strong>6/12/2009</strong>
<strong>Updated information</strong>
Neuropsychiatric events have been reported in some patients taking montelukast (Singulair), zafirlukast (Accolate), and zileuton (Zyflo and Zyflo CR). FDA has requested that manufacturers include a precaution in the drug prescribing information (drug labeling).
Montelukast is used to treat asthma, and the symptoms of allergic rhinitis (sneezing, stuffy nose, runny nose, itching of the nose), and to prevent exercise-induced asthma. Zafirlukast and zileuton are used to treat asthma.
The reported neuropsychiatric events include postmarket cases of agitation, aggression, anxiousness, dream abnormalities and hallucinations, depression, insomnia, irritability, restlessness, suicidal thinking and behavior (including suicide), and tremor.
<em>This information reflects FDA’s current analysis of available data concerning this drug.</em>
<em>To report any serious adverse events associated with the use of this drug, please contact the FDA MedWatch program using the contact information at the bottom of this web page.</em>
<div align="center"><hr align="center" size="2" width="100%" />
<strong>Advice to patients and healthcare professionals</strong>
<ul>
<li>Patients and healthcare professionals should be aware of the potential for neuropsychiatric events with these medications.</li>
<li>Patients should talk with their healthcare providers if these events occur.</li>
<li>Healthcare professionals should consider discontinuing these medications if patients develop neuropsychiatric symptoms.</li>
</ul>
<strong>Background</strong>
In April 2009, FDA completed its review of neuropsychiatric events, (mood and behavioral changes) possibly related to drugs that act through the leukotriene pathway (montelukast, zafirlukast, zileuton). As part of its review, FDA reviewed post-marketing reports and also requested that manufacturers submit all available clinical trial data for these products.
The post-market reports of patients on these medications included cases of neuropsychiatric events. Some reports included clinical details consistent with a drug-induced effect. In the clinical trial data submitted by manufacturers, neuropsychiatric events were not commonly observed. However, the available data were limited because the trials were not designed to look for neuropsychiatric events. Sleep disorders (primarily insomnia) were reported more frequently with all three products compared to placebo.
I am mom to a 15 year old daughter with CF. She has not had an easy path with her CF so far although I'm certain some have had a lot worse. But at 15 she has a port (usually on IV antibiotics 2-6 weeks/year) and has CFRD. She also had a gtube from age 5-14. Even with all those challenges however, she has remained a positive, optimistic person and has always been super compliant with her CF meds and treatments.
But it has been a tough year. She started high school in September.Right before that her CF doc had put her on prednisone then medrol. Shestarted feeling really depressed, moody, not sleeping, etc. Every side effect in the book. She even beganhaving some weird dream like"terrors" at night. Like someone or something was after her. Not unusual when on steroids from what I understand.
But recently, she has had these night "terrors" again. Or more accurately, she has REALIZED she's been having them for a long time. Frighting stuff. Spiders or scary people coming after her. No wonder she was always exhausted in the mornings and found it impossible to get to school. Then I came across the information below about Singulair. Has anyone else experienced anything like this? We have taken her off the Singulair and she seemed at first to be better. But lately she is still bothered by these terror type of events at night. I'm thinking that she was on prednisone and then singulair for so long and suffering with these terrors for so long that they are not just going to go away overnight when we stop the meds. Does anyone else have any experience with this sort of event?
<strong>6/12/2009</strong>
<strong>Updated information</strong>
Neuropsychiatric events have been reported in some patients taking montelukast (Singulair), zafirlukast (Accolate), and zileuton (Zyflo and Zyflo CR). FDA has requested that manufacturers include a precaution in the drug prescribing information (drug labeling).
Montelukast is used to treat asthma, and the symptoms of allergic rhinitis (sneezing, stuffy nose, runny nose, itching of the nose), and to prevent exercise-induced asthma. Zafirlukast and zileuton are used to treat asthma.
The reported neuropsychiatric events include postmarket cases of agitation, aggression, anxiousness, dream abnormalities and hallucinations, depression, insomnia, irritability, restlessness, suicidal thinking and behavior (including suicide), and tremor.
<em>This information reflects FDA’s current analysis of available data concerning this drug.</em>
<em>To report any serious adverse events associated with the use of this drug, please contact the FDA MedWatch program using the contact information at the bottom of this web page.</em>
<div align="center"><hr align="center" size="2" width="100%" />
<strong>Advice to patients and healthcare professionals</strong>
<ul>
<li>Patients and healthcare professionals should be aware of the potential for neuropsychiatric events with these medications.</li>
<li>Patients should talk with their healthcare providers if these events occur.</li>
<li>Healthcare professionals should consider discontinuing these medications if patients develop neuropsychiatric symptoms.</li>
</ul>
<strong>Background</strong>
In April 2009, FDA completed its review of neuropsychiatric events, (mood and behavioral changes) possibly related to drugs that act through the leukotriene pathway (montelukast, zafirlukast, zileuton). As part of its review, FDA reviewed post-marketing reports and also requested that manufacturers submit all available clinical trial data for these products.
The post-market reports of patients on these medications included cases of neuropsychiatric events. Some reports included clinical details consistent with a drug-induced effect. In the clinical trial data submitted by manufacturers, neuropsychiatric events were not commonly observed. However, the available data were limited because the trials were not designed to look for neuropsychiatric events. Sleep disorders (primarily insomnia) were reported more frequently with all three products compared to placebo.